NRx Pharmaceuticals, Inc. NRXP
2.19 USD -0.09 (-3.95%)
Regular-session close
2.19 0.00 0.00%
After hours · Nov 13, 7:11 PM ET
2.17 Day range 2.26
1.68 52-week range 4.62
- YTD
- -19.19%
- 1 year
- -15.44%
News
globenewswire.com NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update WILMINGTON, Del., Nov. 12, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target…
globenewswire.com NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target…
benzinga.com Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
benzinga.com Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51 Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
benzinga.com NRx Pharmaceuticals Receives FDA Approval Of Its Abbreviated New Drug Application For Preservative-Free Ketamine The approval comes ahead of the FDA-announced November 10, approval goal date.Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride…
benzinga.com Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket Civeo shares surged 19.9% after earnings beat estimates and FY2026 sales guidance rose; other premarket movers included SLGB, HUBC and ATEC.
benzinga.com NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge? NRx Pharmaceuticals shares jump 26.69% after hours as investors await details of a regulatory milestone for its ketamine program.
benzinga.com NRx Pharmaceuticals Completes Three Process Validation Lots Of Preservative Free Ketamine Produced Under Commercial Conditions In Anticipation Of Nov. 10 Generic Drug User Fee Amendments Goal Date NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central
benzinga.com NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10 NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, "NRx" or "the Company"), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the
benzinga.com Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50 Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $49 to $50.
benzinga.com NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are…- benzinga.com FDA Reclassifies NRx Pharmaceuticals' Ketamine ANDA Amendment To Minor, Setting New Goal Date For November 10, 2026 Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic…
benzinga.com BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $10 price target.
benzinga.com NRx Pharma’s GeNeuro Announces Award Of European Patent Entitled Anti HERV K Envelope Antibody And Uses Thereof Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the "dark genome" of all people.K Env…- benzinga.com NRx Pharmaceuticals’ HOPE Therapeutics To Deploy Zeta Surgical's Newly FDA-Cleared Zeta TMS Robotic System, With Clinical Staff Now In Training Ahead Of Deployment In Florida HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completing orientation and training at Zeta Surgical's…
- benzinga.com HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
benzinga.com NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. This content is powered by Benzinga APIs. For…- benzinga.com NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of…
- benzinga.com NRx Pharmaceuticals To Host Conference Call And Q&A Session On August 10 To Discuss FDA's Completion Of First-Cycle Review Of Its ANDA For Preservative-Free Ketamine NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on
benzinga.com BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10 BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.
benzinga.com NRx Pharmaceuticals Announces FDA Found No Major Deficiencies In Its First-Cycle Review Of ANDA For Its Preservative-Free Ketamine No major deficiencies related to the drug product, ingredients, proposed labeling, Chemistry, Manufacturing and Controls, or other drug-related review matters. No new clinical, safety, efficacy, or…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock…
- benzinga.com NRx Pharmaceuticals Issues Statement In Response To Kadima Allegations, Citing Arbitration Over Non‑Acquisition By HOPE Therapeutics NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx" or the "Company") today issued the following statement in response to recent public claims made by Kadima Neuropsychiatry Institute
- benzinga.com NRx Pharma’s HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient careAI-powered,…
- benzinga.com NRx Pharma Announces FDA Approval Of Intermediate Population Expanded Access Protocol For Use Of NRX-101, Fixed Dose Combination Of DCS And Lurasidone For Augmentation Of Accelerated TMS D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TMS) in remission from depression and suicidality in several published clinical studies.NRx…
- benzinga.com NRx Pharmaceuticals Prices $20M Public Offering Of 5,714,286 Shares Of Common Stock At A Price Of $3.50/Share To Fund Working Capital And Growth Plans NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering (the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Tetra Technologies Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100M stock offering. XOS, Wellchange, and J-Star are top gainers while Jianzhi, NRx, and Volato are…
benzinga.com NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's Why NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise capital for growth and operations.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com NRx Pharmaceuticals Announces Proposed Underwritten Public Offering Of Common Stock; No Terms Disclosed NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer shares of its common stock, par…
- benzinga.com NRx Pharma's Strategic Partner, Emobot Health, Presents Late-Breaking Poster At 2026 Annual Meeting Of ASCP, Reporting First Pooled Clinical Validation Of EMOCARE EMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first…
- benzinga.com NRx Pharma's HOPE Unit Deploys Zeta Surgical's FDA‑Cleared TMS Navigation System At West Palm Beach Clinic To Deliver Image‑Guided Therapy For Major Depressive Disorder And Other Neurological Conditions Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com NRx Pharma Targets FDA Approvals, Expands Clinics And Advances PTSD Drug Pipeline In 2026 Key highlights from the first quarter of operations under the expanded management team include the following:Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026,…
- benzinga.com NRX Pharmaceuticals Q1 EPS $(0.04) Up From $(0.34) YoY, Sales $1.068M NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.04) per share. This is a 88.24 percent increase over losses of $(0.34) per share from the same period last year. The company…
benzinga.com NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, with a loss of 11 cents per share. FDA clearance received for clinical trial.- benzinga.com NRx Pharma Receives Clearance From FDA To Initiate Clinical Trial Of NRX-101 Vs. Placebo In Patients With Depression And Suicidality Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching…
- benzinga.com NRx Starts Production Of Preservative-Free Ketamine Ahead Of FDA Decision, Expands Manufacturing, Builds Team For Expected Drug Launch NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces initiation of a first…
- benzinga.com HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
- benzinga.com Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49 Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $48 to $49.
- benzinga.com NRx Pharmaceuticals Welcomes The Newly-Signed Presidential Executive Order: Accelerating Medical Treatments For Serious Mental Illness In the Order, the President notes that, "It is the policy of my Administration to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that…
- benzinga.com NRx Pharmaceuticals Receives FDA Letter Regarding Comments On Minor Formatting Changes To Proposed Label For Its Preservative-Free Ketamine Product, The Company Expects To Submit Final Label In April NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx's preservative-free ketamine product. Labeling remains subject to final supervisory…
- benzinga.com BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
- benzinga.com NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000K NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 percent increase over losses of $(0.77) per share from the same period last year. The company…
benzinga.com NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug The FDA signals its willingness to review NRx Pharmaceuticals' NRX-100 NDA, boosting optimism around its depression treatment.- benzinga.com NRx Pharmaceuticals Intends To Submit New Drug Application For NRX-100 By June Following Successful Type-C FDA Guidance Meeting NRXP has received confirmatory minutes from an in-person Type C guidance meeting at the headquarters of the US Food and Drug Administration. The meeting was attended by leaders of the FDA Division of…
- benzinga.com NRx Pharmaceuticals' HOPE Therapeutics Expands Clinic Network With Palm Beach Location Targeting Depression And PTSD With 87% Response Rate Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins,…
- benzinga.com HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $45 HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $40 to $45.